Wilson Therapeutics applies for delisting

May 25, 2018

The public offer by Alexion Pharmaceuticals, Inc. through Alexion Pharma Nordics Holding AB (“Alexion”) for the shares in Wilson Therapeutics AB (publ) (“Wilson”) was declared unconditional today, 25 May 2018. Alexion owns more than 90 per cent of the shares in Wilson and intends to request compulsory acquisition in respect of the remaining shares in Wilson. The acceptance period for Alexion’s offer has been extended up to and including 8 June 2018, 3:00 p.m. CET, to allow remaining shareholders in Wilson to accept the offer.

At the request of Alexion, the Board of Directors of Wilson has resolved to apply for delisting of Wilson’s shares from Nasdaq Stockholm. The last day of trading in Wilson’s shares on Nasdaq Stockholm will be announced as soon as Wilson has received confirmation of such date from Nasdaq Stockholm.

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

For further information please contact:

Jonas Hansson, CEO, Wilson Therapeutics AB
Phone: +46 8 796 00 00
E-mail: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
Kungsgatan 3
SE-111 43 Stockholm